7/1/2013

The European Medicines Agency's Committee for Medicinal Products for Human Use endorsed the approval of Celltrion's Remsima and Hospira's Inflectra. Both drugs are biosimilar versions of Remicade, an injectable rheumatoid arthritis treatment from Johnson & Johnson and Merck.

Full Story:
MedCityNews.com

Related Summaries